The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549 **FORM D** 

## OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00

## **Notice of Exempt Offering of Securities**

| ,  |                            |                     |                           |
|--|----------------------------|---------------------|---------------------------|
| 1. Issuer's Identity                       |                            |                     |                           |
| CIK (Filer ID Number)                      | Previous<br>Names          | None                | Entity Type               |
| 0001094038                                 | TAPIMMUN                   | IF INC              | Corporation               |
| Name of Issuer                             | TAPIMMUN                   |                     | Limited Partnership       |
| Marker Therapeutics, Inc.                  | GENEMAX                    |                     | Limited Liability Company |
| Jurisdiction of Incorporation/Organization |                            | General Partnership |                           |
| DELAWARE                                   |                            |                     | Business Trust            |
| Year of Incorporation/Organization         |                            |                     | Other (Specify)           |
| Over Five Years Ago                        |                            |                     |                           |
| Within Last Five Years (S                  | Specify Year)              |                     |                           |
| Yet to Be Formed                           | , , ,                      |                     |                           |
| 2. Principal Place of Busines              | ss and Contact Information |                     |                           |
| Name of Issuer                             |                            |                     |                           |
| Marker Therapeutics, Inc.                  |                            |                     |                           |
| Street Address 1                           |                            | Street Address 2    |                           |
| 2450 HOLCOMBE BLVD                         |                            | SUITE BCM-A, MS     | 8: BCM251                 |
| City                                       | State/Province/Country     | ZIP/PostalCode      | Phone Number of Issuer    |
| HOUSTON                                    | TEXAS                      | 77021               | 713-400-6400              |
| 3. Related Persons                         |                            |                     |                           |
| Last Name                                  | First Name                 |                     | Middle Name               |
| Vera                                       | Juan                       |                     |                           |
| Street Address 1                           | Street Address 2           |                     |                           |
| 2450 Holcombe Blvd                         | Suite BCM-A, MS            | : BCM251            |                           |
| City                                       | State/Province/C           | ountry              | ZIP/PostalCode            |
| Houston                                    | TEXAS                      |                     | 77021                     |
| Relationship: Executive (                  | Officer 🕡 Director 🔲 Promo | ter                 |                           |
| Clarification of Response (if N            | ecessary):                 |                     |                           |
| Last Name                                  | First Name                 |                     | Middle Name               |
| Eansor                                     | David                      |                     |                           |
| Street Address 1                           | Street Address 2           |                     |                           |
| 2450 Holcombe Blvd                         | Suite BCM-A, MS            | : BCM251            |                           |
| City                                       | State/Province/C           | ountry              | ZIP/PostalCode            |
| Houston                                    | TEXAS                      |                     | 77021                     |
| Relationship: Executive (                  | Officer 🕡 Director 🔲 Promo | ter                 |                           |
| Clarification of Response (if N            | ecessary):                 |                     |                           |
| Last Name                                  | First Name                 |                     | Middle Name               |
| Wilson                                     | John                       |                     |                           |
| Street Address 1                           | Street Address 2           |                     |                           |
| 2450 Holcombe Blvd                         | Suite BCM-A, MS            | : BCM251            |                           |
| City                                       | State/Province/C           | ountry              | ZIP/PostalCode            |
| Houston                                    | TEXAS                      |                     | 77021                     |
| Relationship: Executive 0                  | Officer 🕡 Director 🔲 Promo | ter                 |                           |
| Clarification of Response (if N            | ecessary):                 |                     |                           |

| ,   |   |                           |  |  |  |  |  |  |  |
|---|---|---------------------------|--|--|--|--|--|--|--|
| Last Name   | First Name                                  | Middle Name               |  |  |  |  |  |  |  |
| Knobil  | Katharine                                   |                           |  |  |  |  |  |  |  |
| Street Address 1                                      | Street Address 2                            |                           |  |  |  |  |  |  |  |
| 2450 Holcombe Blvd                                    | Suite BCM-A, MS: BCM251                     |                           |  |  |  |  |  |  |  |
| City  | State/Province/Country                      | ZIP/PostalCode            |  |  |  |  |  |  |  |
| Houston   | TEXAS                                       | 77021                     |  |  |  |  |  |  |  |
| Relationship: Executive Officer Director Promoter     |   |                           |  |  |  |  |  |  |  |
| Clarification of Response (if Necessary):             |   |                           |  |  |  |  |  |  |  |
| Last Name   | First Name                                  | Middle Name               |  |  |  |  |  |  |  |
| Elms  | Steven                                      |                           |  |  |  |  |  |  |  |
| Street Address 1 2450 Holcombe Blvd                   | Street Address 2<br>Suite BCM-A, MS: BCM251 |                           |  |  |  |  |  |  |  |
| City  | State/Province/Country                      | ZIP/PostalCode            |  |  |  |  |  |  |  |
| Houston   | TEXAS                                       | 77021                     |  |  |  |  |  |  |  |
| Relationship: Executive Officer D                     | irector Promoter                            |                           |  |  |  |  |  |  |  |
| Clarification of Response (if Necessary):             |   |                           |  |  |  |  |  |  |  |
| 4. Industry Group                                     |   |                           |  |  |  |  |  |  |  |
| Agriculture   | Health Care                                 | [ Detailing               |  |  |  |  |  |  |  |
| Banking & Financial Services                          | Biotechnology                               | Retailing                 |  |  |  |  |  |  |  |
| Commercial Banking                                    |   | Restaurants               |  |  |  |  |  |  |  |
| Insurance   | Health Insurance                            | Technology                |  |  |  |  |  |  |  |
| Investing   | Hospitals & Physicians                      | Computers                 |  |  |  |  |  |  |  |
| Investment Banking                                    | Pharmaceuticals                             | Telecommunications        |  |  |  |  |  |  |  |
| Pooled Investment Fund                                | Other Health Care                           | Other Technology          |  |  |  |  |  |  |  |
| Is the issuer registered as                           | Manufacturing                               | Travel                    |  |  |  |  |  |  |  |
| an investment company under<br>the Investment Company | Real Estate                                 | Airlines & Airports       |  |  |  |  |  |  |  |
| Act of 1940?  | Commercial                                  | Lodging & Conventions     |  |  |  |  |  |  |  |
| Yes No  | Construction                                |                           |  |  |  |  |  |  |  |
| Other Banking & Financial Service                     |   | Tourism & Travel Services |  |  |  |  |  |  |  |
| Business Services                                     |   | Other Travel              |  |  |  |  |  |  |  |
| Energy  | Residential                                 | Other                     |  |  |  |  |  |  |  |
| Coal Mining   | Other Real Estate                           |                           |  |  |  |  |  |  |  |
| Electric Utilities                                    |   |                           |  |  |  |  |  |  |  |
| Energy Conservation                                   |   |                           |  |  |  |  |  |  |  |
|   |   |                           |  |  |  |  |  |  |  |
| Environmental Services                                |   |                           |  |  |  |  |  |  |  |
| Oil & Gas   |   |                           |  |  |  |  |  |  |  |
| Other Energy  |   |                           |  |  |  |  |  |  |  |
| 5. Issuer Size  |   |                           |  |  |  |  |  |  |  |
| Revenue Range OR                                      | Aggregate Net Asset Value F                 | _                         |  |  |  |  |  |  |  |
| No Revenues   | No Aggregate Net Asset                      | t Value                   |  |  |  |  |  |  |  |
| \$1 - \$1,000,000                                     | \$1 - \$5,000,000                           | •                         |  |  |  |  |  |  |  |
| \$1,000,001 - \$5,000,000                             | \$5,000,001 - \$25,000,00                   |                           |  |  |  |  |  |  |  |
| \$5,000,001 - \$25,000,000                            | \$25,000,001 - \$50,000,0                   |                           |  |  |  |  |  |  |  |
| \$100,000,000   | \$50,000,001 - \$100,000                    | ,000                      |  |  |  |  |  |  |  |
| Over \$100,000,000                                    | Over \$100,000,000                          |                           |  |  |  |  |  |  |  |
| ✓ Decline to Disclose                                 | Decline to Disclose                         | Decline to Disclose       |  |  |  |  |  |  |  |
| Not Applicable  | Not Applicable                              |                           |  |  |  |  |  |  |  |
| 6. Federal Exemption(s) and Exclusion(s               | s) Claimed (select all that apply)          |                           |  |  |  |  |  |  |  |
| Rule 504(b)(1) (not (i), (ii) or (iii))               | Investment Company                          | Act Section 3(c)          |  |  |  |  |  |  |  |
| Rule 504 (b)(1)(i)                                    | Section 3(c)(1)                             | Section 3(c)(9)           |  |  |  |  |  |  |  |
| Rule 504 (b)(1)(ii)                                   | Section 3(c)(2)                             | Section 3(c)(10)          |  |  |  |  |  |  |  |
| Rule 504 (b)(1)(iii)                                  |   |                           |  |  |  |  |  |  |  |

| Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)   | Section 3(c)(3) Section 3(c)(11)  Section 3(c)(4) Section 3(c)(12) |   |  |  |  |  |
|--|--|---|--|--|--|--|
| L  | Section 3(c)(5) Section 3(c)(13)                                   |   |  |  |  |  |
|  | Section 3(c)(6) Section 3(c)(14)                                   |   |  |  |  |  |
| L  | Section 3(c)(7)  |   |  |  |  |  |
| 7. Type of Filing  |  |   |  |  |  |  |
| New Notice Date of First Sale 2024-12-23 Fire Amendment  | rst Sale Yet to Occur  |   |  |  |  |  |
| 8. Duration of Offering  |  |   |  |  |  |  |
| Does the Issuer intend this offering to last more than on  | ne year? Yes No  |   |  |  |  |  |
| 9. Type(s) of Securities Offered (select all that apply  |  |   |  |  |  |  |
| ☑ Equity       ☐ Pooled Investment Fund Interests         ☐ Debt       ☐ Tenant-in-Common Securities         ☐ Option, Warrant or Other Right to Acquire Another Security       ☐ Mineral Property Securities         ☑ Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security       ☐ Other (describe) |  |   |  |  |  |  |
| 10. Business Combination Transaction   |  |   |  |  |  |  |
| Is this offering being made in connection with a busines merger, acquisition or exchange offer?  | s combination transaction, such as a Yes V No                      |   |  |  |  |  |
| Clarification of Response (if Necessary):  |  |   |  |  |  |  |
| 11. Minimum Investment   |  |   |  |  |  |  |
| Minimum investment accepted from any outside investo   | or \$100,000 USD   |   |  |  |  |  |
| 12. Sales Compensation   |  |   |  |  |  |  |
| Recipient  | Recipient CRD Number None  |   |  |  |  |  |
| CANACCORD GENUITY LLC  | 000001020  |   |  |  |  |  |
| (Associated) Broker or Dealer None   | (Associated) Broker or Dealer CRD Number 🕡 None                    | (Associated) Broker or Dealer CRD Number None |  |  |  |  |
| None   | None   |   |  |  |  |  |
| Street Address 1   | Street Address 2   |   |  |  |  |  |
| ONE PENNSYLVANIA PLAZA SUITE 2900  |  |   |  |  |  |  |
| City   | State/Province/Country   | ZIP/Postal Code                               |  |  |  |  |
| New York   | NEW YORK   | 10119   |  |  |  |  |
| State(s) of Solicitation (select all that apply) Check "All States" or check individual States   | tates Foreign/non-US   |   |  |  |  |  |
| DELAWARE  MARYLAND  NEW YORK   |  |   |  |  |  |  |
| Recipient  | Recipient CRD Number None  |   |  |  |  |  |
| Brookline Capital Markets, a division of Arcadia Securities,   | LLC 000044656  |   |  |  |  |  |
| (Associated) Broker or Dealer None   | (Associated) Broker or Dealer CRD Number 🕡 None                    |   |  |  |  |  |
| None   | None   |   |  |  |  |  |
| Street Address 1   | Street Address 2   |   |  |  |  |  |
| 1370 Avenue of the Americas 29th Floor   |  |   |  |  |  |  |
| City   | State/Province/Country   | ZIP/Postal Code                               |  |  |  |  |
| New York   | NEW YORK   | 10019   |  |  |  |  |
| State(s) of Solicitation (select all that apply) Check "All States" or check individual States   | tates Foreign/non-US   |   |  |  |  |  |
| DELAWARE  MARYLAND  NEW YORK   |  |   |  |  |  |  |

| 13. Offering and Sales Amounts  |
|---|
| Total Offering Amount \$16,100,000 USD or Indefinite  |
| Total Amount Sold \$16,100,000 USD  |
| Total Remaining to be Sold \$0 USD or Indefinite  |
| Clarification of Response (if Necessary):   |
| 14. Investors   |
| Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.   |
| Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:   |
| 15. Sales Commissions & Finder's Fees Expenses  |
| Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.  |
| Sales Commissions \$816,000 USD Estimate  |
| Finders' Fees \$0 USD Estimate  |
| Clarification of Response (if Necessary):   |
| 16. Use of Proceeds   |
| Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount. |
| \$0 USD Estimate  |
| Clarification of Response (if Necessary):   |
| Signature and Submission  |
| Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.   |
| Terms of Submission   |

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

| Issuer                    | Signature     | Name of Signer | Title                   | Date       |
|---------------------------|---------------|----------------|-------------------------|------------|
| Marker Therapeutics, Inc. | /s/ Juan Vera | Juan Vera      | Chief Executive Officer | 2024-12-30 |

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

<sup>\*</sup> This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.